Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.

Abstract

EBV-induced lymphoproliferative disease (EBV-LPD) is a disorder most commonly associated with the immunocompromise that follows allogeneic organ transplantation. In patients receiving T cell-depleted bone marrow from HLA-mismatched or HLA-matched unrelated donors, the incidence of EBV-LPD is particularly high, ranging from 5 to 30%. Administration of EBV-specific cytotoxic T lymphocytes may be one means of preventing and treating this disease. We now describe a method that allows the routine and timely preparation of large numbers of such cells to allow their safe administration to bone marrow transplant recipients. We also describe how these cells may be genetically marked before infusion, to determine their fate and disposition in vivo.

050100150'99'01'03'05'07'09'11'13'15'17
Citations per Year

833 Citations

Semantic Scholar estimates that this publication has 833 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Smith1995ProductionOG, title={Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.}, author={Clyde A. Smith and Cedric C Y Ng and H. E. Heslop and M S Holladay and Sandy L. Richardson and E Victoria Turner and Susan K. Loftin and C K P Li and Malcolm K. Brenner and Cliona M Rooney}, journal={Journal of hematotherapy}, year={1995}, volume={4 2}, pages={73-9} }